IMPLICATIONS FOR PATIENT CARE: This study highlights the feasibility of hK2 as a prostate cancer target and supports continued investigation of h11B6 or other hK2-targeting agents in the treatment of mCRPC. The gene discussed is HK2; the disease is Familial prostate cancer.